Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Stephen S. Dominy net worth and biography

Stephen Dominy Biography and Net Worth

Insider of Cortexyme

Stephen S. Dominy, M.D., has served as a member of our board of directors since December 2015 and as our Chief Scientific Officer since April 2016. Prior to co-founding Cortexyme, Dr. Dominy served as a Division Director at San Francisco General Hospital and as Associate Professor of Psychiatry at the University of California, San Francisco School of Medicine from 2006 to 2016. Dr. Dominy holds a B.S. in Pharmacy from The Ohio State University College of Pharmacy and an M.D. from the Wright State University Boonshoft School of Medicine.

How do I contact Stephen S. Dominy?: The corporate mailing address for Dr. Dominy and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]. Learn More on Stephen S. Dominy's contact information.
Has Stephen S. Dominy been buying or selling shares of Cortexyme?: Stephen S. Dominy has not been actively trading shares of Cortexyme in the last ninety days. Most recently, on Friday, November 12th, Stephen S. Dominy bought 763 shares of Cortexyme stock. The stock was acquired at an average cost of $14.40 per share, with a total value of $10,987.20. Learn More on Stephen S. Dominy's trading history.
Who are Cortexyme's active insiders?: Cortexyme's insider roster includes Michael Detke (Insider), Stephen Dominy (Insider), David Lamond (Director), Christopher Lowe (CFO), Casey Lynch (CEO), and Margaret Mcloughlin (Director). Learn More on Cortexyme's active insiders.

Stephen S. Dominy Insider Trading History at Cortexyme

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2021	Buy	763	$14.40	$10,987.20

Stephen S. Dominy Buying and Selling Activity at Cortexyme

Cortexyme Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.06

$1.00

$1.10

50 Day Range

MA: $1.18

$0.99

$1.95

2 Week Range

Now: $1.06

$1.78

$40.66

Volume

57,652 shs

Average Volume

620,672 shs

Market Capitalization

$31.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4